300363-41-1

Basic information

• Product Name: (+)-1,1-dimethylethyl [(1R)-1-({[(1,1-dimethylethyl)(diphenyl)silyl]oxy}methyl)prop-2-en-1-yl]carbamate
• Synonyms: (+)-1,1-dimethylethyl [(1R)-1-({[(1,1-dimethylethyl)(diphenyl)silyl]oxy}methyl)prop-2-en-1-yl]carbamate
• CAS NO: 300363-41-1
• Molecular Weight: 425.643
• Mol File: 300363-41-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (+)-1,1-dimethylethyl [(1R)-1-({[(1,1-dimethylethyl)(diphenyl)silyl]oxy}methyl)prop-2-en-1-yl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-1,1-dimethylethyl [(1R)-1-({[(1,1-dimethylethyl)(diphenyl)silyl]oxy}methyl)prop-2-en-1-yl]carbamate(300363-41-1)
• EPA Substance Registry System: (+)-1,1-dimethylethyl [(1R)-1-({[(1,1-dimethylethyl)(diphenyl)silyl]oxy}methyl)prop-2-en-1-yl]carbamate(300363-41-1)

Safety Data

• Hazardous Substances Data: 300363-41-1(Hazardous Substances Data)

Upstream product

• 913344-40-8 tert-butyl N-formyl carbamate 
• 862157-37-7 C₂₂H₂₈O₄Si 
• 1315127-91-3 (-)-1,1-dimethylethyl [(1R)-1-({[(1,1-dimethylethyl)(diphenyl)silyl]oxy}methyl)prop-2-en-1-yl]formylcarbamate 
• 91177-57-0 tert-butyl (1R)-1-(hydroxymethyl)-3-(methylsulfanyl)propylcarbamate 
• 34619-03-9 tert-butyldicarbonate 

Downstream Products

• 1234693-31-2 (+)-methyl (2E,6R)-7-{[(1,1-dimethylethyl)(diphenyl)silyl]oxy}-6-({[(1,1-dimethylethyl)oxy]carbonyl}amino)hept-2-enoate 
• 300363-45-5 N-[1-(tert-butyl-diphenyl-silanyloxymethyl)-allyl]-4-methyl-N-(3-oxo-3-pyrrolidin-1-yl-propyl)-benzenesulfonamide 
• 300363-44-4 3-[[1-(tert-butyl-diphenyl-silanyloxymethyl)-allyl]-(toluene-4-sulfonyl)-amino]-propionic acid 
• 300363-43-3 3-[[1-(tert-butyl-diphenyl-silanyloxymethyl)-allyl]-(toluene-4-sulfonyl)-amino]-propionic acid methyl ester 
• 300363-42-2 3-[1-(tert-butyl-diphenyl-silanyloxymethyl)-allylamino]-propionic acid methyl ester 

Relevant articles and documents

Design, synthesis and biological evaluation of isoxazole-based CK1 inhibitors modified with chiral pyrrolidine scaffolds

In this study, we report on the modification of a 3,4-diaryl-isoxazole-based CK1 inhibitor with chiral pyrrolidine scaffolds to develop potent and selective CK1 inhibitors. The pharmacophore of the lead structure was extended towards the ribose pocket of